Key result
Standard pharmacological therapies that improve survival in systolic heart failure, including ACE inhibitors, ARBs, and beta-blockers, have failed to demonstrate similar survival benefits in patients with heart failure with preserved ejection fraction.
Traditional HFrEF therapies have not demonstrated significant mortality benefits in HFpEF, leaving symptom management and risk factor control as the primary treatment strategies.
HFpEF care should emphasize symptom relief and risk factor control; confirms lack of mortality benefit from HFrEF therapies and leaves open targeted trials.
Despite a decline in many forms of cardiovascular disease, heart failure (HF) continues to increase. Heart failure with preserved ejection fraction (HFpEF) is common, especially among persons with multiple comorbidities. HFpEF presents many challenges for clinicians due to the incomplete understanding of the underlying mechanisms and lack of consensus on the most effective strategies for treatment. Angiotensin and beta receptor-blocking drugs, which form the cornerstone for the treatment of systolic HF, have failed to show similar benefits in patients with impaired diastolic function. This article provides an overview of drug therapy for HFpEF, including newer agents now under investigation.
No takes yet. Share an insight, caveat, or question.
Patricia Howard (2015) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Pharmacological therapies (Diuretics, ACE inhibitors, ARBs, Beta Blockers, Digoxin, Aldosterone Antagonists, Statins, Neprilysin Inhibitors) was evaluated. Standard pharmacological therapies that improve survival in systolic heart failure, including ACE inhibitors, ARBs, and beta-blockers, have failed to demonstrate similar survival benefits in patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: